Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn).

IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL BMJ Evidence-Based Medicine Pub Date : 2025-11-26 DOI:10.1136/bmjebm-2023-112487
Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, Sophie Gulliver, Hannah Hesselgreaves, Abha Mehndiratta, Francis Ruiz, Kirti Tyagi, Olivia Wu, Javier Guzman, Eleanor Grieve
{"title":"Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn).","authors":"Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, Sophie Gulliver, Hannah Hesselgreaves, Abha Mehndiratta, Francis Ruiz, Kirti Tyagi, Olivia Wu, Javier Guzman, Eleanor Grieve","doi":"10.1136/bmjebm-2023-112487","DOIUrl":null,"url":null,"abstract":"<p><p>An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).A framework developed by the University of Glasgow was used to review three 'hta's commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each 'hta'. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.</p>","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s29-s37"},"PeriodicalIF":7.6000,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Evidence-Based Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjebm-2023-112487","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).A framework developed by the University of Glasgow was used to review three 'hta's commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each 'hta'. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卫生技术评估物有所值吗?估计印度卫生技术评估的投资回报(HTAIn)。
低收入和中等收入国家对卫生技术评估(HTA)的投资不断增加,使决策者对卫生技术评估的价值和投资回报(ROI)产生了更大的兴趣。然而,很少有研究量化了HTA对卫生系统的价值。本评估旨在量化印度HTA机构(HTAIn)的影响和投资回报率。格拉斯哥大学开发的框架用于审查HTAIn在2018年至2020年期间委托的三个“hta”,并考虑到投资这些过程的机会成本。成本包括维修保养的固定成本及进行每项维修保养的成本。可归属收益是通过从已实现收益中减去反事实收益(在没有HTA的情况下可能实现的收益)来计算的。HTAIn隶属于印度政府卫生和家庭福利部卫生研究司。它的设立是为了促进印度医疗保健领域透明和循证决策的进程。HTA帮助决策者了解备选行动方案的后果,并选择以最低成本产生最佳结果的方案。卫生保健服务的制度化被视为支持全民健康覆盖的关键,这是支持更好地分配有限资源、控制成本和实现健康最大化的一种手段。净健康效益是我们衡量价值的标准。HTAIn的投资回报率是通过汇总可归属收益并将其与投资成本相抵消来计算的。我们的研究结果表明,投资于HTA的回报率为9:1,如果全面实施HTA的建议,这一回报率有可能增加到71:1。不同干预措施与疾病之间ROI的变异性为5:1 ~ 40:1。虽然HTAIn需要财政投资,但它是对资源的有效利用。潜在的更大的影响和干预之间的投资回报率的可变性强调了在HTA中规划实施和良好的主题选择的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMJ Evidence-Based Medicine
BMJ Evidence-Based Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
8.90
自引率
3.40%
发文量
48
期刊介绍: BMJ Evidence-Based Medicine (BMJ EBM) publishes original evidence-based research, insights and opinions on what matters for health care. We focus on the tools, methods, and concepts that are basic and central to practising evidence-based medicine and deliver relevant, trustworthy and impactful evidence. BMJ EBM is a Plan S compliant Transformative Journal and adheres to the highest possible industry standards for editorial policies and publication ethics.
期刊最新文献
FDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs. It is time to improve the quality of service standards using evidence-based practice. Advancing the 'Choosing Wisely' campaign to reduce low-value care in China. Cluster-randomised controlled trials. Trump's statements about acetaminophen and the problem of epistemic corrections.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1